![Jens Schneider-Mergener](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jens Schneider-Mergener is the founder of Pharvaris NV, which was founded in 2015.
He was the Chief Executive Officer at Shire Orphan Therapies GmbH.
He also served as the Chief Executive Officer at AdrenoMed AG from 2019 to 2021.
Dr. Schneider-Mergener received his undergraduate degree from the University of Bielefeld and his doctorate from Ludwig-Maximilians-Universität München.
| Sociétés | Poste | Fin |
|---|---|---|
AdrenoMed AG
 AdrenoMed AG Pharmaceuticals: MajorHealth Technology Develops a drug to decrease mortality in severe sepsis | Directeur Général | 01/01/2021 |
| PHARVARIS N.V. | Fondateur | - |
Shire Orphan Therapies GmbH
 Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Develops novel drugs | Président | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 5 |
|---|---|
Shire Orphan Therapies GmbH
Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Develops novel drugs | Health Technology |
University of Bielefeld
 University of Bielefeld Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ludwig-Maximilians-Universität München
 Ludwig-Maximilians-Universität München Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AdrenoMed AG
AdrenoMed AG Pharmaceuticals: MajorHealth Technology Develops a drug to decrease mortality in severe sepsis | Health Technology |
Pharvaris NV
 Pharvaris NV BiotechnologyHealth Technology Develops and commercializes oral bradykinin B2 receptor antagonists | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
